KALA - Kala Pharmaceuticals, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles technology, with focus on the treatment of eye diseases.
IPO Date: July 20, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $6.96M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.33 | 4.51%
Avg Daily Range (30 D): $0.05 | 7.98%
Avg Daily Range (90 D): $0.10 | 7.51%
Institutional Daily Volume
Avg Daily Volume: 1.13M
Avg Daily Volume (30 D): 2.82M
Avg Daily Volume (90 D): 1.03M
Trade Size
Avg Trade Size (Sh.): 260
Avg Trade Size (Sh.) (30 D): 418
Avg Trade Size (Sh.) (90 D): 361
Institutional Trades
Total Institutional Trades: 197
Avg Institutional Trade: $1.53M
Avg Institutional Trade (30 D): $1.04M
Avg Institutional Trade (90 D): $1.04M
Avg Institutional Trade Volume: M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.38M
Avg Closing Trade (30 D): $1.51M
Avg Closing Trade (90 D): $1.51M
Avg Closing Volume: 7.61K
 
News
Dec 5, 2025 @ 7:36 PM
KALA BIO Announces Closing of $10 Million Register...
Source: David Lazar
Sep 29, 2025 @ 5:14 PM
Crude Oil Falls Sharply; Carnival Posts Upbeat Ear...
Source: Avi Kapoor
Sep 29, 2025 @ 5:06 PM
12 Health Care Stocks Moving In Monday's Intraday ...
Source: Benzinga Staff Writer
Sep 29, 2025 @ 2:11 PM
Nasdaq Jumps 150 Points; US Pending Home Sales Ris...
Source: Avi Kapoor
Aug 8, 2025 @ 12:18 PM
Kala Bio (KALA) Q2 Loss Widens 15%
Source: Jesterai
Financials
  TTM Q1 2026 Q4 2025
Basic EPS $-21.32 $-.14 $.86
Diluted EPS $-21.32 $-.14 $.86
Revenue $M $M $M
Gross Profit
Net Income / Loss $-1.58M $-1.62M $.69M
Operating Income / Loss $-1.72M $-1.8M $-10.23M
Cost of Revenue
Net Cash Flow $-1.54M $-5.79M $-13.54M
PE Ratio    
Splits
May 11, 2026 1:50
Oct 21, 2022 1:50
Aug 26, 2022 1.00:1